Our Funding

Grant Support

• NIH/NIAID: Public HIV Drug Resistance Database 1R01AI68581 (2006 - 2018)
• Gilead Sciences: HIV Drug Resistance Database (2015 - 2016)
• Bristol Myers Squibb Transmitted Antiretroviral Resistance 2003 to 2012. Effect of Deep Sequencing on Prevalence of Drug Resistance Mutations and Response to First-Line Therapy (2014 - 2015)
• Merck Transmitted Antiretroviral Resistance and Low-Abundance Drug Resistance Mutations: Implications for Raltegravir plus Truvada Therapy (2014 - 2015)
• Bill & Melinda Gates Foundation: Consensus HIV-1 Drug Resistance Mutations for Point-Of-Care (POC) Genotypic Resistance Tests (2013 - 2014)
• NIH/NIGMS: Targeting Ensembles of Drug Resistant Protease Variants Project: Conformational Flexibility of HIV-1 Protease in vivo. PO1 (2002 - 2011)
• Gilead Sciences: Hepatitis B Minority Variants in Patients Treated with Lamivudine and/or Interferon (2009 - 2011)
• Merck: Raltegravir: Clinical Use, Virological Response, and Drug Resistance in a Large Clinic-Based Population (2009 - 2010)
• Hoffman La Roche Ultra-Deep Sequencing to Detect Resistance to Small Molecule Hepatitis C Inhibitors (2009 - 2011)
• California HIV Research Program: Clinical Significance of Minority HIV-1 Variants (2009 - 2011)
• NIH/Blood Systems Research Institute (R01 subcontract): Metagenomic Analysis of the Human Virome (2007 - 2011)
• NIH/NIAID 1R01 AI46148-01: Identification of Multidrug-Resistant HIV-1 Isolates (1998 - 2008)
• California University-Wide AIDS Research Program: Optimizing Clinical HIV Genotypic Resistance Interpretation (2004 - 2006)

Unrestricted Gifts

Support HIVdbMake a Gift >>